SEARCH

SEARCH BY CITATION

References

  • 1
    Vardiman JW, Harris N, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 22922302.
  • 2
    Lichtman MA. The stem cell in the pathogenesis and treatment of myelogenous leukemia: a perspective. Leukemia 2001; 15: 14891494.
  • 3
    Jordan CT. Unique molecular and cellular features of acute myelogenous leukemia stem cells. Leukemia 2002; 16: 559562.
  • 4
    Guzman ML, Upchurch D, Grimes B, et al. Expression of tumor-suppressor genes interferon regulatory factor 1 and death-associated protein kinase in primitive acute myelogenous leukemia cells. Blood 2001; 94: 21772179.
  • 5
    Blair A, Hogge DE, Ailles LE, et al. Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo. Blood 1997; 89: 31043112.
  • 6
    Blair A, Hogge DE, Sutherland HJ. Most acute myeloid leukemia progenitor cells with long-term proliferative ability in vitro and in vivo have the phenotype CD34+/CD71/HLADR. Blood 1998; 92: 43254335.
  • 7
    Blair A, Sutherland HJ. Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117). Exp Hematol 2000; 28: 660671.
  • 8
    Green CL, Loken M, Buck D, et al. Discordant expression of AC133 and AC141 in patients with myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). Leukemia 2000; 14: 770772.
  • 9
    Nilsson L, Grundstrom I, Arvidsson I, et al. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. Blood 2000; 96: 20122021.
  • 10
    Von Lom K, Hagenmeijer A, Smit E, et al. Cytogenetic clonality analysis in myelodysplastic syndrome: monosomy 7 can be demonstrated in the myeloid and in the lymphoid lineage. Leukemia 1995; 9: 18181821.
  • 11
    Saitoh K, Miura I, Takahashi N. Fluorescence in situ hybridization of progenitor cells obtained by fluorescence-activated cell sorting for the detection of cells affected by chromosome abnormality trisomy 8 in patients with myelodysplastic syndromes. Blood 1998; 92: 28862892.
  • 12
    Miura I, Kobayashi Y, Takahashi N, et al. Involvement of natural killer cells in patients with myelodysplastic syndrome carrying monosomy 7 revealed by the application of fluorescence in situ hybridization to cells collected by means of fluorescence-activated cell sorting. Br J Haematol 2000; 110: 876879.
  • 13
    Amin HM, Jilani I, Estey EH, et al. Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome. Blood 2003; 102: 18661868.
  • 14
    Benito AL, Bryant E, Loken MR, et al. NOD/SCID mice transplanted with marrow from patients with myelodysplastic syndrome (MDS) show long-term propagation of normal but not clonal human precursors. Leuk Res 2003; 27: 425436.
  • 15
    Hirai H. Molecular mechanisms of myelodysplastic syndrome. Jpn J Clin Oncol 2003; 33: 153160.
  • 16
    Xie D, Hofmann WK, Mori N, et al. Allelotype analysis of the myelodysplastic syndrome. Leukemia 2000; 14: 805810.
  • 17
    Mori N, Morosetti R, Hoflehnere E, et al. Allelic loss in the progression of myelodysplastic syndrome. Cancer Res 2000; 60: 30393042.
  • 18
    Kaeferstein A, Drug U, Tiesmeier J, et al. The emergence of a C/EBPalpha mutation in the clonal evolution of MDS towards secondary AML. Leukemia 2003; 17: 343349.
  • 19
    Au W, Fung A, Man C, et al. Aberrant p15 gene promoter methylation in therapy-related myelodysplastic syndrome and acute myeloid leukaemia: clinicopathological and karyotypic associations. Br J Haematol 2003; 120: 10621065.
  • 20
    Uchida T, Kinoshita T, Nagai H, et al. Hypermethylation of the p15INK4b gene in myelodysplastic syndromes. Blood 1997; 90: 14031409.
  • 21
    Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Methylation of p15(INK4B) is common, is associated with deletion of genes on chromosome are 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2003; 17: 18131819.
  • 22
    Quesnel B, Guillerm G, Verecque R, et al. Methylation of the p15INK4b gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 1998; 91: 29852990.
  • 23
    Teofili L, Martini M, Di Mario A, et al. Expression of p15ink4b gene during megakaryocytic differentiation of normal and myelodysplastic hematopoietic pogenitors. Blood 2001; 98: 495497.
  • 24
    Fuchigami K, Mori H, Matsuo T, et al. Absolute number of circulating CD34+ cells is abnormally low in refractory anemias and extremely high in RAEB and RAEB-t; novel pathologic features of myelodysplastic syndromes identified by highly sensitive flow cytometry. Leuk Res 2000; 24: 163174.
  • 25
    Vehmeyer K, Haase D, Alves F. Increased peripheral stem cell pool in MDS: an indication of disease progression? Leuk Res 2001; 25: 955959.
  • 26
    Sultana TA, Harada H, Ito K, et al. Expression and functional analysis of granulocyte colony-stimulating factor receptors on CD34++ cells in patients with myelodysplastic syndrome (MDS) and MDS-acute myeloid leukaemia. Br J Haematol 2003; 121: 6375.
  • 27
    Cilloni D, Gottardi E, Messa F, et al. Significant correlation between the degree of WT1 expression and the international prognostic scoring system score in patients with myelodysplastic syndromes. J Clin Oncol 2003; 21: 19881995.
  • 28
    Lepelley P, Foulani S, Grardel N, et al. Expression of lung resistance protein and correlation with other drug resistance proteins and outcome in myelodysplastic syndromes. Leuk Lymph 1998; 29: 547551.
  • 29
    Hofmann W-K, de Vos S, Komor M, et al. Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. Blood 2002; 100: 35533560.
  • 30
    Miyazato A, Ueno S, Ohmine K, et al. Identification of myelodysplastic syndrome-specific genes by DNA microarray analysis with purified hematopoietic stem cell fraction. Blood 2001; 98: 422427.
  • 31
    Ohyashiki JH, Sashida G, Tauchi T, et al. Telomeres and telomerase in hematologic neoplasia. Oncogene 2002; 21: 680687.
  • 32
    Kuramoto K, Ban S, Oda K, et al. Chromosomal instability and radiosensitivity in myelodysplastic syndrome cells. Leukemia 2002; 16: 22532258.
  • 33
    Ueda M, Ota J, Yamashita Y, et al. DNA microarray analysis of stage progression mechanism in myelodysplastic syndrome. Br J Haematol 2003; 123: 288296.
  • 34
    Osterveld M, de Witte T. Intensive treatment strategies in patients with high-risk myelodysplastic syndrome and secondary acute myeloid leukemia. Blood Rev 2000; 14: 182189.
  • 35
    Aivado M, Gattermann N, Bottomley S. X chromosome inactivation ratios in female carriers of X-linked sideroblastic anemia. Blood 2001; 97: 40004002.
  • 36
    Bouscary D, Chen YL, Guesnu M. Activity of the cas-pase-3/CPP32 enzyme is increased in “early stage” myelodysplastic syndromes with excessive apoptosis, but caspase inhibition does not enhance colony formation in vitro. Exp Hematol 2000; 28: 784791.
  • 37
    Shimazaki K, Ohshima K, Suzumiya J, et al. Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromes. Br J Haematol 2000; 110: 584590.
  • 38
    Washington LT, Jilani I, Estey E, Albitar M. Less apoptosis in patients with 5q- syndrome than in patients with refractory anemia. Leuk Res 2002; 26: 899902.
  • 39
    Albitar M, Manshouri T, Shen Y, et al. Myelodysplastic syndrome is not merely “preleukemia.” Blood 2002; 100: 791798.
  • 40
    Pecci A, Travaglino E, Kiersy C, et al. Apoptosis in relation to CD34 antigen expression in normal and myelodysplastic bone marrow. Acta Haematol 2003; 109: 2934.
  • 41
    Peddie CM, Wolf CR, McLellan LI, et al. Oxidative DNA damage in CD34+ myelodysplastic cells is associated with intracellular redox chages and elevated plasma tumour necrosis factor-alpha concentration. Br J Haematol 1997; 99: 625631.
  • 42
    Lin CW, Manshouri T, Jilani I, et al. Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome. Leuk Res 2002; 26: 551559.
  • 43
    Huh YO, Jilani I, Estey E, et al. More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia. Leukemia 2002; 16: 22492252.
  • 44
    Yoshida Y. The aplasiamyelodysplasia enigma: a re-emerging question. Int J Hematol 1999; 70: 6567.
  • 45
    Parker JE, Mufti GJ. The role of apoptosis in the pathogenesis of the myelodysplastic syndromes. Int J Hematol 2001; 73: 416428.
  • 46
    Boudard D, Vasselon C, Bertheas MF, et al. Expression and prognostic significance of Bcl-2 family proteins in myelodysplastic syndromes. Am J Hematol 2002; 70: 115125.
  • 47
    Parker JE, Mufti GJ, Rasool F, et al. The role of apoptosis, proliferation, and the Bcl-2 related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 2000; 96: 39323938.
  • 48
    Hellstrom-Lindberg E, Schmidt-Mende J, Forsblom AM, et al. Apoptosis in refractory anemia with ringed sideroblasts is initiated at the stem cell level and associated with increased activation of caspases. Br J Heamatol 2001; 112: 714726.
  • 49
    Schmidt-Mende J, Tehranchi R, Forsblom AM, et al. Granulocyte colony-stimulating factor inhibits Fas-triggered apoptosis in bone marrow cells isolated from patients with refractory anemia with ringed sideroblasts. Leukemia 2001; 15: 742751.
  • 50
    Tehranchi R, Fadell B, Forsblom AM, et al. Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. Blood 2003; 101: 10801086.
  • 51
    Gattermann N. From sideroblastic anemia to the role of mitochondrial DNA mutations in myelodysplastic syndromes. Leuk Res 2000; 24: 141151.
  • 52
    Plasilova M, Zivny J, Jelinek J, et al. TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors. Leukemia 2002; 16: 6773.
  • 53
    Sawanobori M, Yamaguchi S, Hasegawa M, et al. Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes. Leuk Res 2003; 27: 583591.
  • 54
    Shetty V, Hussaini S, Broady-Robinson L, et al. Intramedullary apoptosis of hematopoietic cells in myelodysplastic syndrome patients can be massive: apoptotic cells recovered from high-density fraction of bone marrow aspirates. Blood 2000; 15: 13881392.
  • 55
    Stasi R and Amadori S. Infliximab chimeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes. Br J Haematol 2002; 116: 334337.
  • 56
    Novitzky N, Mohamed R, Finlayson J, et al. Increased apoptosis of bone marrow cells and preserved proliferative capacity of selected progenitors predict for clinical response to anti-inflammatory therapy in myelodysplastic syndromes. Exp Hematol 2000; 28: 941949.
  • 57
    Rosenfeld C, Bedell C. Pilot study of recombinant human soluble tumor necrosis factor receptor (TNFR: Fc) in patients with low risk myelodysplastic syndrome. Leuk Res 2002; 26: 721724.
  • 58
    Muller A, Lange K, Gaiser T, et al. Expression of angiopoietin-1 and its receptor TEK in hematopoietic cells from patients with myeloid leukemia. Leuk Res 2002; 26: 163168.
  • 59
    Soligo D, Servida F, Delia D, et al. The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant hematopoietic progenitor cells to the proteasome inhibitor PSI. Br J Haematol 2001; 113: 126135.
  • 60
    Morgan MA, Dopl O, Reuter CW. Cell-cycle-dependent activation of mitogen-activated protein kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of Ras signaling. Blood 2001; 14: 18231834.
  • 61
    Parker J, Mufti GJ. Ras and myelodysplasia: lessons from the last decade. Semin Hematol 1996; 33: 206.
  • 62
    Scheele JS, Ripple D, Lubbert M. The role of ras and other low molecular weight guanine nucleotide (GTP)-grinding proteins during hematopoeitic cell differentiation. Cell Mol Life Sci 2000; 57: 19501963.
  • 63
    Kalina U, Hofmann WK, Koschmieder S, et al. Alteration of c-mpl-mediated signal transduction in CD34(+) cells from patients with myelodysplastic syndromes. Exp Hematol 2000; 28: 11581163.
  • 64
    Hoefsloot LH, van Amelsvoort MP, Broeders LCAM, et al. Erythropoietin-induced activation of STAT5 is impaired in the myelodysplastic syndrome. Blood 1997; 89: 16901700.
  • 65
    Killick SB, Marsh JC, Gordon-Smith EC, et al. Effects of antithymocyte globulin on bone marrow CD34+ aplastic anemia and myelodysplasia. Br J Haematol 2000; 108: 582591.
  • 66
    Kochenderfer JN, Kobayashi S, Wieder ED, Su C, et al. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood 2002; 100: 36393645.
  • 67
    Alvado M, Rong A, Stadler M, et al. Favorable response to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a “non-clonal” pattern of X-chromosome inactivation in bone marrow cells. Euro J Haematol 2002; 68: 210216.
  • 68
    Saunthararajah Y, Nakamura R, Nam JM, et al. HLA-DR15 (DR2) is over represented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002; 100: 15701574.
  • 69
    Sloand EM, Kim S, Fuhrer M, et al. Fas-mediated apoptosis is important in regulating cell replication and death in trisomy 8 hematopoietic cells but not in cells with other cytogenetic abnormalities. Blood 2002; 100: 44274432.
  • 70
    Sloand EM, Fuhrer M, Johnson S, et al. Preferential inhibition of trisomy 8 progenitor cell growth by autologous CD8+V-beta-restricted T cells in patients with trisomy 8 myelodysplasia. Blood 2002; 100: 166a.
  • 71
    Ma L, Delforge M, Verhoef GEG, et al. The immunophenotype and function of dendritic cells in myelodysplastic syndromes. Blood 2002; 100: 166a.
  • 72
    Moldrem J, Jiang Y, Stetler-Stevenson M, et al. Hematologic response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T cell receptor Vβ profiles. Br J Haematol 1998; 102: 1314.
  • 73
    Culligan DJ, Cachia P, Whittaker A, et al. Clonal lymphocytes are detectable in only some cases of MDS. Br J Haematol 1992; 81: 346.
  • 74
    Tauro S, Hepburn MD, Peddie CM, et al. Functional disturbance of marrow stromal microenvironment in the myelodysplastic syndromes. Leukemia 2002; 16: 785790.
  • 75
    Tennant GB, Walsh V, Truran LN, et al. Abnormalities of adherent layers grown from bone marrow of patients with myelodysplasia. Br J Haematol 2000; 111: 953962.
  • 76
    Alvi S, Shaher A, Shetty V, et al. Successful establishment of long-term bone marrow cultures in 103 patients with myelodysplastic syndromes. Leuk Res 2001; 25: 941954.
  • 77
    Flores-Figueroa E, Gutierrez-Espindola G, Montesions JJ, et al. In vitro characterization of hematopoietic microenvironment cells from patients with myelodysplastic syndrome. Leuk Res 26:2002;677686.
  • 78
    Hu X, Zuckermann KS. Transforming growth factor: signal transduction pathways, cell cycle mediation, and effects on hematopoiesis. J Hematother Stem Cell Res 2001; 10: 6774.
  • 79
    Brunner B, Gunsilius E, Schumacher P, et al. Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia. J Hematother Stem Cell Res 2002; 11: 119125.
  • 80
    Bellamy WT, Richter L, Sirjani D, et al. Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001; 97: 14271434.
  • 81
    Curly CR, Spencer CM. Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndromes. Drugs 2001; 61: 641684.
  • 82
    Galanopoulos A, Kritidou-Griva E, Gligori J, et al. Treatment of patients with myelodysplastic syndrome with amifostine. Leuk Res 2001; 25: 665671.
  • 83
    List AF. New approaches to the treatment of myelodysplasia. The Oncologist 2002; 7: 3949.
  • 84
    Rosenfeld C, List A. A hypothesis for the pathogenesis of myelodysplastic syndrome: implications for new therapies. Leukemia 2000; 14: 28.
  • 85
    Stover JA, Lejeune C, Stevernson D, et al. Molecular class prediction of progression to acute myeloid leukemia in patients with myelodysplastic syndromes. Proc AACR 2003; 44: 923, 4033a.